⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
PPLPHARMA - Technical Analysis with Chart Patterns & Indicators
Last Updated Time : 20 Dec 25, 03:55 pm
Back to Technical ListTechnical Rating: 3.3
| Stock Code | PPLPHARMA | Market Cap | 22,743 Cr. | Current Price | 171 ₹ | High / Low | 273 ₹ |
| Stock P/E | 32.2 | Book Value | 58.2 ₹ | Dividend Yield | 0.08 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 186 ₹ | DMA 200 | 198 ₹ |
| Chg in FII Hold | -0.59 % | Chg in DII Hold | 0.64 % | PAT Qtr | 196 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 22.7 | MACD | -6.50 | Volume | 28,15,670 | Avg Vol 1Wk | 30,04,571 |
| Low price | 165 ₹ | High price | 273 ₹ | PEG Ratio | 1.45 | Debt to equity | 0.12 |
| 52w Index | 5.59 % | Qtr Profit Var | -6.54 % | EPS | 5.32 ₹ | Industry PE | 30.6 |
📊 Technical Analysis
- Chart Patterns: Stock is trading near strong support (165 ₹) with resistance around 186–198 ₹ (DMA levels).
- Moving Averages: Current price (171 ₹) is below both 50 DMA (186 ₹) and 200 DMA (198 ₹), indicating bearish bias.
- RSI: At 22.7, the stock is oversold, suggesting potential rebound.
- MACD: Negative (-6.50), confirming weak momentum and bearish crossover.
- Bollinger Bands: Price is near lower band, signaling oversold condition and possible mean reversion.
- Volume Trends: Current volume (28,15,670) is slightly below 1-week average (30,04,571), showing reduced participation.
📈 Momentum & Signals
- Short-term Momentum: Weak, but oversold indicators suggest potential bounce from support.
- Entry Zone: 165–172 ₹ (near strong support).
- Exit Zone: 185–200 ₹ (resistance at DMA levels).
- Trend Status: Currently consolidating near support with bearish undertone.
✅ Positive
- EPS of 5.32 ₹ supports earnings visibility.
- ROCE (12.4%) and ROE (9.74%) show moderate returns.
- DII holdings increased (+0.64%), showing domestic investor confidence.
- Debt-to-equity ratio of 0.12 indicates low leverage.
⚠️ Limitation
- Stock trading below both 50 DMA and 200 DMA.
- RSI and MACD show weak momentum.
- PEG ratio of 1.45 suggests valuation is slightly expensive relative to growth.
- Dividend yield is negligible (0.08%).
📉 Company Negative News
- Quarterly profit variation shows decline (-6.54%).
- FII holdings decreased (-0.59%), showing reduced foreign investor confidence.
- Stock has corrected sharply from 52-week high of 273 ₹.
📈 Company Positive News
- Quarterly PAT improved from 113 Cr. to 196 Cr.
- DII holdings increased, showing domestic support.
- Stock trading near long-term support levels, offering potential accumulation opportunity.
🏭 Industry
- Industry PE is 30.6, close to PPLPHARMA’s PE of 32.2, suggesting fair valuation.
- Pharmaceutical sector growth supported by demand for generics and specialty formulations.
📝 Conclusion
- PPLPHARMA is technically weak but oversold, hinting at possible rebound from support.
- Best strategy: Accumulate near 165–172 ₹ and book profits around 185–200 ₹.
- Overall trend: Consolidation with bearish bias, awaiting reversal signals.
NIFTY 50 - Today Top Technical Picks Stock Picks
NEXT 50 - Today Top Technical Picks Stock Picks
MIDCAP - Today Top Technical Picks Stock Picks
SMALLCAP - Today Top Technical Picks Stock Picks